Go Backs
HomeCategoriesStatesCheck Your Home
Go Backs

Track product recalls and safety alerts from CPSC, FDA, NHTSA, and USDA. Stay informed and keep your family safe.

Browse

  • Categories
  • States
  • Check Your Home
  • Risk Levels

Agencies

  • CPSC
  • FDA Food
  • FDA Drug
  • FDA Device
  • FDA Veterinary
  • NHTSA
  • USDA

Company

  • About
  • FAQ
  • Contact
  • Terms of Service
  • Privacy Policy
Buy Me a Coffee

Recall data is sourced from official U.S. government agencies (CPSC, FDA, NHTSA, USDA) and processed using AI to improve readability. This site is not affiliated with or endorsed by any government agency. Always refer to the original agency notice for authoritative information.

ยฉ 2026 Go Backs. All rights reserved.

Medium RiskFDA Drug
Medications & Supplements/Prescription Drugs

Viatris Carvedilol Tablets Recalled for Weight and Thickness Defects

Agency Publication Date: November 16, 2022
Share:
Sign in to monitor this recall

Summary

Viatris Inc has recalled 2,794 bottles of Carvedilol (generic Coreg) 25 mg tablets, a prescription medication used to treat heart failure and high blood pressure. The recall was issued because the tablets were found to exceed the required specifications for weight and thickness. No injuries or adverse incidents have been reported in connection with this recall to date.

Risk

Tablets that are heavier or thicker than specified may contain an inconsistent dosage of the medication. This could potentially lead to patients receiving more or less of the prescribed drug than intended, which may interfere with the management of serious heart conditions.

What You Should Do

  1. This recall affects 500-count bottles of Carvedilol Tablets, USP, 25 mg, manufactured for Mylan Pharmaceuticals Inc. (NDC 0378-3634-05).
  2. Check your medication bottle for lot number 3150116 with an expiration date of February 2025 (2/2025).
  3. If you have health concerns or are unsure about your medication, contact your healthcare provider or pharmacist immediately. Return any unused product from the affected lot to the place of purchase for a refund, throw it away, or contact the manufacturer for further instructions.
  4. Call the FDA Consumer Complaint hotline at 1-888-723-3332 (1-888-SAFEFDA) for additional assistance.

Your Remedy Options

You have 2 options:

๐Ÿ’ฐOption 1: Full Refund
How to: Contact your healthcare provider or pharmacist for guidance, or return any unused product to the place of purchase for a refund
๐Ÿ—‘๏ธOption 2: Dispose of Product
How to: Throw the product away. For prescription medications, a DEA take-back location or pharmacy mail-back program is preferred when available.

Affected Products

Product: Carvedilol Tablets, USP, 25 mg (500-count bottles)
Variants: 25 mg, 500-count
Lot Numbers:
3150116 (Exp 2/2025)
NDC:
0378-3634-05

Manufactured by Mylan Pharmaceuticals Inc. in Morgantown, WV 36505 or India.

Additional Information

Agency: Food and Drug Administration (FDA)
Event ID: 91038
Status: Resolved
Manufacturer: Viatris Inc
Sold By: Pharmacies
Manufactured In: India, United States
Units Affected: 2,794 bottles
Distributed To: Nationwide

Were You Affected by This Recall?

If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.

Find an Attorney

This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.

AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.

Sources: FDA iRES ยท Raw API Response

openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.